Wearable Artificial Organs Inc.

Wearable Artificial Organs Inc. is a for-profit organization and manufacturer of goods specializing in the development of innovative medical devices, particularly wearable artificial kidneys. Registered with SAM.gov since June 2017, the company focuses on creating advanced healthcare solutions for patients with end-stage kidney disease (ESKD). Their work primarily involves research, development, and clinical testing of miniaturized dialysis technologies aimed at improving the quality of life for ESKD patients while reducing healthcare costs.

Through federal contract awards, Wearable Artificial Organs Inc. has engaged in cutting-edge medical research and development projects. A notable example is their Cost-Plus-Fixed-Fee contract awarded by the Department of the Army Medical Command in September 2019. This contract, valued at $3,683,215.80, was designated as a small business set-aside and focused on the development of an Extracorporeal Life Support (ECLS) Reduced Dialysate Device. The project, scheduled for completion in April 2021, demonstrates the company's capability to contribute to advanced life support technologies for military and civilian applications.

Wearable Artificial Organs Inc. has also secured significant federal grant awards to further its research and development efforts. A prime example is the $459,824 Project Grant (R44DK139891) awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program. This grant, running from July 2024 to May 2026, supports the development and clinical testing of a Wearable Artificial Kidney (WAK) device. The project involves a two-part clinical trial to evaluate the WAK's performance in ESKD patients, aiming to provide the FDA with data for market approval. Additionally, the company received a $2,999,590 Project Grant (HT94252410501) from the Department of Defense's Military Medical Research and Development program in June 2024. This grant, extending through December 2025, focuses on developing Wearable Artificial Kidneys, further emphasizing the company's commitment to transforming healthcare for both military personnel and the general public through innovative biomedical research.